Trials / Completed
CompletedNCT04908176
A Drug-drug Interaction Study of Avapritinib and Midazolam
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.
Conditions
- Gastrointestinal Stromal Tumors
- GIST
- Non-resectable Advanced Solid Tumors
- Recurrent or Unresectable Central Nervous System (CNS) Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avapritinib | avapritinib tablets |
| DRUG | midazolam | midazolam syrup |
Timeline
- Start date
- 2022-08-24
- Primary completion
- 2024-03-01
- Completion
- 2024-05-10
- First posted
- 2021-06-01
- Last updated
- 2024-12-13
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04908176. Inclusion in this directory is not an endorsement.